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Urinary Tract Infections (UTIs) are
amongst the most common infectious
 diseases and carry a significant impact on patient quality 
of life and health care costs. Despite that, there is no  
well-established recommendation for a “standard”
 prophylactic antibiotic management to prevent UTI
 recurrences. The majority of patients undergoes long-term
antibiotic treatment that severely impairs the normal micro-
biota and increases the risk of development of multidrug-
resistant microorganisms. In this scenario, the use of
 phytotherapy to both alleviate symptoms related to UTI and
decrease the rate of symptomatic recurrences is an attrac-
tive alternative. Several recently published papers report
 conflicting findings and cannot give confident recommenda-
tions for the everyday clinical practice. A new approach to
the management of patients with recurrent UTI might be to
use nutraceuticals or phytotherapy after an accurate assess-
ment of the patient`s risk factors. No single compound or
mixture has been identified so far as the best preventive
approach in patients with recurrent UTI. We reviewed our
non-antibiotic approach to the management of recurrent
UTI patients in order to clarify the evidence-base for the
commonly used  substances, understand their pharmacoki-
netics and  pharmacodynamics in order to tailor the best way
to improve patient’s quality of life and reduce the rate of
antibiotic  resistance.
Lack of a gold-standard recommendation and the risk of
increasing antibiotic resistance is the reason why we need
alternatives to antibiotics in the management of urinary
tract infections (UTIs). A tailored approach according to
bacterial characteristics and the patient risk factors profile
is a  promising option. 
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INTRODUCTION
Urinary tract infections (UTIs) are amongst the most
common community-acquired infectious diseases, with
annual costs estimated to be higher than $1.5 billion in
the United States (1-2). The impact on public health is
significant due to the high recurrence rate and the effect
on patients’ quality of life (4). The mortality rate must
also be taken into account (reported to be as high as 1%
in men and 3% in women due to development of
pyelonephritis and urosepsis). In particular, after an ini-
tial UTI, approximately 20-30% of women with a UTI
will have a second UTI within 6 months, and 3% will
experience a third UTI during that time period (4-5). In
consequence, women with recurrent UTIs (rUTIs)
reported a high indirect cost as a result of the number of
working days lost (6). The majority of these patients are
women with recurrent bacterial cystitis or acute
pyelonephritis, and the causative pathogens can usually
be eradicated with a short course of oral antimicrobial
therapy. However, the antibiotic treatment can lead to
long term impairment of the normal microbiota of the
vagina and gastrointestinal tract and to the development
of multidrug-resistant micro-organisms (7-9). Moreover,
there is no well-established recommendation for a ‘stan-
dard’ prophylactic antibiotic management to prevent
UTI recurrence (10). Furthermore, many women have a
number of signs and symptoms of UTIs without any evi-
dence of bacterial presence (11). In this sense, the use of
phytotherapy to alleviate symptoms related to UTI and
decrease the rate of symptomatic recurrence seems a
good alternative which is nowadays more commonly
used. There are many good reasons for this approach e.g.
the low side-effects, low costs and a high level of com-
pliance. Also important are the low rate of efficacy of
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standard preventive measures with subsequent patient
disappointment and drop-outs (3, 12). Traditionally,
nutraceuticals and phytotherapy have been used to pre-
vent rUTIs in otherwise healthy women. Although the
results from a number of clinical studies have supported
their benefits, the efficacy of nutraceuticals and phy-
totherapy on prevention of rUTIs remains controversial,
due to heterogeneity of published studies in terms of
methodology and the reported findings such as trial
design; inclusion/exclusion criteria; patient characteris-
tics; outcome measures, as well as heterogeneity of the
compounds used.
The latest Cochrane reviews on UTI management con-
cluded as follows:
– Chinese herbal medicine alone or in conjunction with
antibiotics may be beneficial for treating recurrent
UTIs during the acute phase of infection and may
reduce the recurrent UTI incidence for at least six
months post-treatment (13).
– No significant benefit was demonstrated for probiotics
compared with placebo or no treatment, but a benefit
cannot be ruled out as the data were few, and derived
from small studies with poor methodological report-
ing (3).
– Given the large number of dropouts/withdrawals from
studies (mainly attributed to the acceptability of con-
suming cranberry products particularly juice, over
long periods), and poor evidence for prevention of
UTI, cranberry juice cannot currently be recommend-
ed for the prevention of UTIs (14).
The lack of a standard approach for the management of
patient with recurrent UTI and the need to reduce the
use of antibiotics suggest to re-think current practice in
UTI management. In this perspective, the nutraceutical
or phytotherapic approach to recurrent UTIs should be
based on a full evaluation of the clinical situation, patient
risk factors and the characteristics of the bacteria (e.g.
Escherichia coli, adherent to vaginal and bladder epithe-
lial cells). This includes assessment of symptomatic or
asymptomatic bacteriuria; the disease symptoms/charac-
teristics themselves (number or recurrences); the
patient’s behavior (use of a spermicide, diaphragm,
delayed postcoital micturition, hormonal status; other
risk factors); such as ABO-blood-group non-secretor
phenotype, bowel function and water intake (4, 15-17).
A comprehensive assessment may guide and suggest the
best nutraceutical or phytotherapic approach and
improve the treatment outcome. The aim of the present
manuscript is to review the published data about the role
of nutraceuticals and phytotherapy in the management
of patients affected by recurrent UTI and also to address
compounds that can modify the patient’s related risk fac-
tors and improve the treatment outcome.
STATE OF THE ART: 
INTERNATIONAL GUIDELINES RECOMMENDATIONS
The latest version of European Association of Urology
(EAU) guidelines on urological infections states that
there are many non-antimicrobial measures for preven-
tion of recurrent UTIs but only a few of them are based
on well designed studies which are needed to make evi-
dence-based recommendations (18). In particular, EAU
guidelines highlight that there is no convincing benefit
for lactobacillus products or cranberry extracts as pro-
phylaxis of recurrent UTI (18). The Scottish Intercollegiate
Guidelines Network confirmed the recommendations
from the EAU guidelines, highlighting that cranberry
products (juice, tablets, capsules) are not standardized
and the concentrations of active ingredients are not
known; hence the concentration may also fluctuate
between batches of the same product (19). There is no
evidence to support the effectiveness of cranberry prod-
ucts for treating symptomatic episodes of UTI (19). The
Society of Obstetricians and Gynaecologists of Canada`s
guidelines suggest to inform the patients about the effi-
cacy of cranberry products in reducing recurrent urinary
tract infections (IA) (20). Moreover, they suggest to not
use probiotics and vaccines due to lack of demonstrated
efficacy (II-2C) (20).
Take home message
• International guidelines agree that there is no convinc-
ing benefit for the use of nutraceuticals and/or phy-
totherapy as prophylaxis of recurrent UTIs.
• New RCTs are needed.
ACTUAL SCENARIO: 
ALTERNATIVE NON-ANTIBIOTIC MEASURES
Contemporary reviews identify four alternative com-
pounds for non-antibiotic management of recurrent
UTIs:
– Cranberry
– Probiotics
– Chinese herbal medicine
– D-mannose
Cranberry extracts
A Cochrane review from 2008 concluded that cranberry
products significantly reduced the incidence of UTIs at
12 months (RR 0.65, 95% CI 0.46-0.90) compared with
placebo/control in women with recurrent UTIs (21). In a
more recent Cochrane review it was concluded that cran-
berry products did not significantly reduce the occur-
rence of symptomatic UTI in women with recurrent UTIs
(14). The changed view is based on the inclusion of two
additional trials in their meta-analysis (14). In these two
RCTs the effectiveness of cranberry extract was com-
pared with low-dose antibiotic prophylaxis (14).
McMurdo et al. concluded that trimethoprim had a limit-
ed advantage over cranberry extract in the prevention of
recurrent UTIs in older women (22). In addition
Beerepoot et al. showed that cranberry capsules are less
effective than low-dose (480 mg) trimethoprim/sul-
famethoxazole in the prevention of recurrent UTIs in
premenopausal women (23). Vaccinium macrocarpon,
named also American cranberry, is a rich source of
polyphenols that show several in vitro properties,
including antibacterial, antiviral, antimutagenic, anticar-
cinogenic, antitumorigenic, antiangiogenic, anti-inflam-
matory, and antioxidant effects (27). Moreover, cranber-
ry extract is a promising therapy due to the fact that it is
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an anti-adhesive agent against E. coli strains and thus
prevent the development of antibiotic resistance (2). On
the other hand, it has been demonstrated that uropatho-
genic bacteria may have an intestinal origin and the
intestinal tract could be an alternative site where the
active components of cranberry extract may interact with
E. coli decreasing its infectivity (24). Several authors
demonstrated that some extracts from cranberry
decrease the pathogenicity of Proteus mirabilis by limiting
urothelial cell invasion and improving the mucosal
immunity to uropathogens (25-26). 
Probiotics
Probiotics are defined as “a preparation of, or a product
containing viable, defined micro-organisms in sufficient num-
bers, which alter the microflora (by implantation or colo-
nization) in a host compartment and by that exert beneficial
health effects in this host” (3, 28). The hypothesis is that
probiotics are able to establish a barrier against infectious
pathogens ascending the urinary tract, colonizing, and
subsequently causing infection (3, 29). The latest
Cochrane review showed that probiotics were not supe-
rior to placebo in reducing the risk of recurrent sympto-
matic bacterial UTI. The conclusion was based on 6
studies with (352 participants (RR 0.82, 95% CI 0.60 to
1.12; I2=23%). Hence the data were derived from small
studies with poor methodological quality (3). On the
other hand the reported evidences could not rule out a
reduction or increase in recurrent UTI in women with
recurrent UTI who use prophylactic probiotics. One
RCT did not provide sufficient evidence to conclude on
the effect of probiotics versus antibiotics (3).
Chinese herbal medicine
Chinese herbal medicine is a part of Traditional Chinese
Medicine and represents a complex of herbal formulae
usually comprising 10 to 15 different herbs (13).
Chinese herbal medicine formulae may be standardized
or individualized according to specific needs and
patients’ characteristics (13). The hypothesis supporting
the efficacy of Chinese herbal medicine is based on in
vitro research suggesting that some commonly used
Chinese herbs may confer significant diuretic, antibiotic,
immune enhancing, antipyretic, anti-inflammatory and
pain relieving effects (13). The latest Cochrane review,
including 7 RCTs with a total of 542 women, concluded
that Chinese herbal medicine alone or in conjunction
with antibiotics may be useful in treating recurrent UTIs
during the acute phase of an infection and may reduce
the incidence of recurrent UTI for at least six months
post-treatment (13). However, this evidence is based on
a small number of poor quality studies with severe bias
that should be taken into account.
D-mannose
D-mannose is a sugar that has an important role in human
metabolism, especially in the glycosylation of certain pro-
teins. The hypothesis is that D-mannose inhibits bacterial
adherence to uroepithelial cells (30). In fact, in vitro and
in vivo animal studies demonstrated that D-mannose can
inhibit the adhesion of Type 1 fimbriae of the uropatho-
genic bacteria to uroepithelial cells (31). Only one RCT
evaluated its effect as preventive agent in recurrent UTI.
Kranjc˘ec et al., in a study of 98 women, showed that
patients in D-mannose group and Nitrofurantoin group
had a significantly lower risk of recurrent UTI episode
during prophylactic therapy compared to patients in the
no prophylaxis group (RR 0.239 and 0.335, P < 0.0001)
(30). These preliminary findings are promising, but sup-
plementary clinical trials are essential.
Take home messages
• Cranberry products did not significantly reduce the
occurrence of symptomatic UTI in women with recur-
rent UTIs.
• Probiotics are not superior to placebo in reducing the
risk of recurrent symptomatic bacterial UTI.
• Chinese herbal medicine may be useful for treating
recurrent UTIs during the acute phase of infection and
may reduce the incidence of recurrent UTI for at least
six months post-treatment. This evidence is based on a
small number of patients and low quality studies.
• No well-done studies have been performed about the
use of D-mannose in preventing recurrence among
UTI patients.
TOO MANY ANTIBIOTICS: 
DOCTORS NEED TO CHANGE COURSE!
Increasing antimicrobial resistance has stimulated inter-
est in non-antibiotic prophylaxis of recurrent urinary
tract infections. This is particularly due to the recent
alarming increase of the extended spectrum beta-lacta-
mase (ESBL)-producing Enterobacteriaceae prevalence
among outpatients with UTI (32-33). Thus, antimicro-
bial resistance has become a major worldwide health
problem during recent years. Several strategies have been
developed to reduce the alarming increase of resistant
bacteria (34-36). Phytotherapy and nutraceuticals may
be considered an alternative approach for reducing the
recurrences among UTI patients. In fact, patients with
recurrent UTIs are increasingly asking their healthcare
professionals about the value of taking non-antibiotic
products. The non-antibiotic approach, however, should
be based on a correct and deep knowledge about the real
efficacy and tolerability of phytotherapy compounds. All
physicians should update themselves on the latest evi-
dences on non-antibiotic approaches to recurrent UTIs
and suggest products according to international guide-
lines and latest reviews. The main arguments for using a
non-antibiotic approach to prevent recurrence among
UTI patients are as follows: The use of antibiotic pro-
phylaxis for recurrent UTI is not generally accepted; the
risk of bacterial resistance is already high and still
increasing; the tolerability and the compliance to non-
antibiotic products is high; preliminary study findings
are promising. While long-term antibiotic prophylaxis
might efficiently inhibit new intravesical bacterial growth
during the treatment period, infections are likely to rec-
cur when the prophylactic treatment ends (37-38).
Take home messages
• Contemporary antimicrobial resistance rate is alarm-
ing.
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• Phytotherapy and nutraceuticals may be considered a
feasible strategy to reduce indiscriminate use of antibi-
otics.
ASSESSMENT OF PATIENTS’ BEHAVIOUR
AND BACTERIAL RELATED RISK FACTORS
Hooton et al. developed a simple risk prediction model
based on the number of days with intercourse per week
and the use of contraceptives (diaphragm and spermi-
cide) for predicting the risk of UTI recurrence (39).
Hooton showed that an unmarried, 24-year-old female
university student who had sexual intercourse had a risk
of UTI that was 2.6-fold greater than that of a similar stu-
dent who had no intercourse in the previous week (39).
Hooton was a pioneer in highlighting the role of risk-
predicting tools in the management of women with
recurrent UTI1. Recently, Cai et al. developed and vali-
dated a nomogram that accurately predicts the recur-
rence risk of urinary tract infection at 12 months, and
which can assist in identifying women at high risk of
symptomatic recurrence that can be suitable candidates
for a prophylactic strategy (40). In this model they found
the following independent predictors of UTI recurrence:
number of sexual partners, bowel function, type of
pathogens isolated (Gram-positive/negative), hormonal
status, number of UTI recurrences and previous treat-
ment of asymptomatic bacteriuria (40). In this model
they excluded use of food supplements because of the
high variability of products used. Cai et al. also found
that the most important factors affecting the risk of new
recurrences were: bowel function, presence of Gram
negative strains, asymptomatic bacteriuria treatment and
having had 3 or more than 3 UTI episodes (40). The
importance of bowel function for development of UTI is
well known and is related to the fecal-perineal-urethral
contamination by enteric bacteria (40). The risk is of UTI
is increased by constipation as demonstrated by Loening-
Baucke et al. (41). The same authors demonstrated that
constipation treatment results in the disappearance of
recurrent urinary tract infections in all patients who had
no anatomical abnormality of the urinary tract (41).
What about Gram negatives? Cai et al. found that the
presence of Gram-negative bacteria (E. coli) is associated
with a higher likelihood of recurrence (40) due to three
reasons:
– E. coli is the most common pathogen in UTI patients (1).
– E. coli isolated from recurrent UTI has the greatest
propensity of the uropathogenic bacteria to adhere to
the uroepithelial cells of women with recurrent UTI as
compared with bacteria from women without recur-
rent infection (42).
– E. coli is able to adhere to the bladder epithelium,
invade the cells and form intracellular bacterial com-
munities, which can remain quiescent reservoirs able
to cause new recurrences when reactivated (38).
Recently, Cai et al. found that antibiotic treatment of
asymptomatic bacteriuria in young women with recur-
rent UTI is not only unnecessary, but harmful (8-9). This
is due to the fact that in women undergoing antibiotic
treatment, the rate of E. coli decreased over time, where-
as the prevalence of E. faecalis increased gradually, sug-
gesting that E. faecalis might be an important defense
mechanism that effectively interferes with the establish-
ment of many important enteric pathogens, such as E.
coli (8-9). In this sense, the use of non-antibiotic
approach should be preferred because it doesn’t interfere
with the normal commensal bowel flora. 
RISK FACTOR ASSESSMENT AS A GUIDE TO TREATMENT
Assessment of the risk for recurrence is not only impor-
tant for predicting the probability of a new recurrence
but also for the development of a tailored therapeutic
approach on the basis of patient’s characteristics. A con-
stipated patient, for example, should be informed about
the relationship between the constipation and the risk of
new UTI. A nutraceutical or phytotherapic approach act-
ing on the bowel function should be preferred.
Moreover, a patient who reported more than 3 episodes
of previous UTI and correlation with sexual intercourses
should be treated with nutraceutical products that are
able to interfere with the E. coli adhesion to urothelial
cell and invasion.                  
Furthermore, a correct non-antibiotic approach should
work against one or more of the following infection
mechanisms:
– Reduction of the bacterial load in the intestinal reser-
voir with concomitant correction of the constipation
– Reduction of the spread of E. coli from the perineal
zone to the urethra and bladder.
– Reduction of the adhesion and invasion of uropathogens
to the urothelial cells.
– Mobilization of the immune system against the intra-
cellular bacterial communities avoiding reactivation
and new symptomatic recurrences.
We have no an ideal nutraceutical or phytotherapic com-
pound so far that is able to act in all the above ways to
decrease the risk of recurrence. Even if cranberry extracts
seem to be able to act along more than one pathway,
there are limitations due to the pharmacokinetic and
pharmacological characteristics of this compound. As
discussed above, Cranberry extracts are able to reduce
the adherence of E. coli to the urothelial cells and reduce
the adherence of bacterial strains also to the intestinal
cells. However, possible reasons for the inefficacy of
cranberry extracts found in the cited RCTs should also
be taken into account. Firstly, multi-step processing of
cranberry production leads to a substantial loss of phy-
tochemicals (through elimination of rich fractions like
skin and seeds), which are further damaged by thermal
degradation, as well as oxidation by polyphenol oxidase
and peroxidase (38). Moreover, the exact concentration
of active metabolites on the action site and the pharma-
cokinetics of cranberry extracts is unknown. There are
other plant extracts that have shown interesting results
in the prevention of UTI recurrences. Rafsanjany et al.
demonstrated that a mixture of extracts from Betula spp.
(birch), Orthosiphon stamineus (Java tea) and Urtica spp.
(nettles) is able to reduce the adherence of the pathogen
to the host cell. The same results have been obtained by
Cai et al. who demonstrated that a compound with sol-
idago, orthosiphon, birch and cranberry extracts is able
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to reduce the microbial colonization in patients with
indwelling urinary catheters (43). However, this mixture
is not able to cover all mechanisms of infection.
CONCLUSIONS
The lack of a gold-standard for the treatment of recurrent
UTIs and the risk of provoking resistances among the
pathogenic bacteria are two important reasons why we
need non-antibiotic alternatives for the management of
recurrent UTIs. A promising alternative is a tailored
approach based on a comprehensive assessment of
patient related risk factor and the characteristics of the
causative pathogen. Better knowledge about the action of
natural substances will enable us to develop targeted
non-antibiotic prevention of recurrent urinary tract
infections.
AUTHOR CONTRIBUTIONS
Cai T. designed the study; Tamanini I. performed the
research; Cai T. and Tamanini I. wrote the paper;
Wagenlehner F., Kulchavenya E., Tandogdu Z., Bonkat G.,
Bartoletti R. and Bjerklund Johansen T. revised the paper.
Language Revision: Prof. John Denton from Department of
Modern Philology, University of Florence, revised the paper. 
REFERENCES
1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary
tract infections: epidemiology, mechanisms of infection and treat-
ment options. Nat Rev Microbiol. 2015; 13:269-84.
2. Tao Y, Pinzón-Arango PA, Howell AB, Camesano TA. Oral con-
sumption of cranberry juice cocktail inhibits molecular-scale adhe-
sion of clinical uropathogenic Escherichia coli. J Med Food. 2011;
14:739-45.
3. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing
urinary tract infections in adults and children Cochrane Database
Syst Rev. 2015; 12:CD008772.
4. Silverman JA, Schreiber HL 4th, Hooton TM, Hultgren SJ. From
physiology to pharmacy: developments in the pathogenesis and
treatment of recurrent urinary tract infections. Curr Urol Rep.
2013; 14:448-56. 
5. Foxman B. Epidemiology of urinary tract infections: incidence,
morbidity, and economic costs. Dis Mon. 2003; 49:53-70. 
6. François M, Hanslik T, Dervaux B, et al. The economic burden of
urinary tract infections in women visiting general practices in
France: a cross-sectional survey. BMC Health Serv Res. 2016;
16:365. 
7. Kostakioti M, Hultgren SJ, Hadjifrangiskou M. Molecular blue-
print of uropathogenic Escherichia Coli virulence provides clues
toward the development of anti virulence therapeutics. Virulence.
2012; 3:592-594.
8. Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic
bacteriuria in young women with recurrent urinary tract infections:
to treat or not to treat? Clin Infect Dis. 2012; 55:771-7.
9. Cai T, Nesi G, Mazzoli S, et al. Asymptomatic bacteriuria treat-
ment is associated with a higher prevalence of antibiotic resistant
strains in women with urinary tract infections. Clin Infect Dis.
2015; 61:1655-61. 
10. Nosseir SB, Lind LR, Winkler HA. Recurrent uncomplicated uri-
nary tract infections in women: a review. J Womens Health. 2012;
12:347-354. 
11. Chuang FC, Kuo HC. Increased urothelial cell apoptosis and
chronic inflammation are associated with recurrent urinary tract
infection in women PLoS One. 2013; 8:e63760. 
12. Frumenzio E, Maglia D, Salvini E, et al. Role of phytotherapy asso-
ciated with antibiotic prophylaxis in female patients with recurrent uri-
nary tract infections. Arch Ital Urol Androl. 2013; 85:197-9.
13. Flower A, Wang LQ, Lewith G, et al. Chinese herbal medicine
for treating recurrent urinary tract infections in women. Cochrane
Database Syst Rev. 2015; 6:CD010446
14. Jepson RG, Williams G, Craig JC. Cranberries for preventing
urinary tract infections. Cochrane Database Syst Rev. 2012;
10:CD001321. 
15. Adatto K, Doebele KG, Galland L, Granowetter L. Behavioral
factors and urinary tract infection. JAMA. 1979; 241:2525-6. 
16. Czaja CA, Stamm WE, Stapleton AE, et al. Prospective cohort
study of microbial and inflammatory events immediately preceding
escherichia coli recurrent urinary tract infection in women. J Infect
Dis. 2009; 200:528-36. 
17. Wagenlehner FM, Vahlensieck W, Bauer HW, et al. Prevention
of recurrent urinary tract infections. Minerva Urol. Nefrol. 2013;
65:9-20. 
18. European Association of Urology Guidelines - http://uroweb.org/
wp-content/uploads/19-Urological-infections_LR2.pdf - access on
August 2016.
19. http://www.sign.ac.uk/guidelines/fulltext/88/section3.html#3_5_1
- Scottish Intercollegiate Guidelines Network - Healthcare
Improvement Scotland, Gyle Square, 1 South Gyle Crescent,
Edinburgh EH12 9EB. access on August 2016.
20. http://sogc.org/wp-content/uploads/2013/01/gui250CPG1011E
_001.pdf - Society of Obstetricians and Gynaecologists of Canada
guidelines - access on August 2016.
21. Jepson RG, Craig JC. Cranberries for preventing urinary tract
infections. Cochrane Database Syst Rev. 2008; 1:CD001321. 
22. McMurdo ME, Argo I, Phillips G, et al. Cranberry or trimetho-
prim for the prevention of recurrent urinary tract infections? A ran-
domized controlled trial in older women. J. Antimicrob. Chemother.
2009; 63:389-395.
23. Beerepoot MA ter RG, Nys S, van derWal WM, et al. Cranberries
vs. antibiotics to prevent urinary tract infections: A randomized dou-
ble-blind noninferiority trial in premenopausal women. Arch. Intern.
Med. 2011; 171:1270-1278. 
24. Johnson JR, Russo TA, Brown JJ, Stapleton A. PapG alleles of
Escherichia coli strains causing first-episode or recurrent acute cys-
titis in adult women. J Infect Dis. 1998; 12:97-101. 
25. Hopkins WJ, Elkahwaji J, Beierle LM, et al. Vaginal mucosal
vaccine for recurrent urinary tract infections in women: results of a
phase 2 clinical trial. J Urol. 2007; 12:1349-1353.
26. Amalaradjou Mar, Narayanan A, Venkitanarayanan K. Trans-
cinnamaldehyde decreases attachment and invasion of uropathogen-
ic Escherichia coli in urinary tract epithelial cells by modulating vir-
ulence gene expression. J Urol. 2011; 12:1526-1531. 
27. Blumberg JB, Camesano TA, Cassidy A, et al. Cranberries and
their bioactive constituents in human health. Adv Nutr. 2013;
4:618-32. 
5Archivio Italiano di Urologia e Andrologia 2017; 89, 1
Nutraceuticals and urinary tract infection management 
Cai_Stesura Seveso  04/04/17  09:01  Pagina 5
Archivio Italiano di Urologia e Andrologia 2017; 89, 1
T. Cai, I. Tamanini, E. Kulchavenya, T. Perepanova, B. Köves, F.M.E. Wagenlehner, Z.Tandogdu, G. Bonkat, R. Bartoletti, T.E. Bjerklund Johansen
6
28. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbi-
otics - approaching a definition. Am J Clin Nutr. 2001; 73(2
Suppl):361S-364S. 
29. Bruce AW, Reid G. Intravaginal instillation of lactobacilli for the
prevention of recurrent urinary tract infections. Can Journal
Microbiol. 1988; 34:339-43. 
30. Kranjc˘ec B, Papeš D, Altarac S. D-mannose powder for pro-
phylaxis of recurrent urinary tract infections in women: a random-
ized clinical trial. World J Urol. 2014; 32:79-84. 
31. Altarac S, Papes D. Use of D-mannose in prophylaxis of recur-
rent urinary tract infections (UTIs) in women. BJU Int. 2014;
113:9-10. 
32. Al-Mayahie S, Al Kuriashy JJ. Distribution of ESBLs among
Escherichia coli isolates from outpatients with recurrent UTIs and
their antimicrobial resistance. J Infect Dev Ctries 2016; 10:575-83. 
33. Gupta K, Scholes D, Stamm WE. Increasing prevalence of
antimicrobial resistance among uropathogens causing acute uncom-
plicated cystitis in women. JAMA. 1999; 281:736-738. [
34. Cai T, Verze P, Brugnolli A, et al. Adherence to European
Association of Urology Guidelines on Prophylactic Antibiotics: An
Important Step in Antimicrobial Stewardship. Eur Urol. 2016;
69:276-83. 
35. Charani E, Cooke J, Holmes A. Antibiotic stewardship
 programmes--what's missing? J Antimicrob Chemother. 2010;
65:2275-7. 
36. Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic
bacteriuria in young women with recurrent urinary tract infections:
to treat or not to treat? Clin Infect Dis. 2012; 55:771-7. 
37. Eells SJ, Bharadwa K, McKinnell JA, Miller LG. Recurrent uri-
nary tract infections among women: Comparative effectiveness of 5
prevention and management strategies using a Markov chain Monte
Carlo model. Clin Infect Dis. 2014; 58:147-160. 
38. Lüthje P, Brauner A. Novel Strategies in the Prevention and
Treatment of Urinary Tract Infections. Pathogens. 2016; 27:5. 
39. Hooton TM, Scholes D, Hughes JP, et al. A prospective study of
risk factors for symptomatic urinary tract infection in young women.
N Engl J Med. 1996; 335:468-74. 
40. Cai T, Mazzoli S, Migno S, et al. Development and validation of
a nomogram predicting recurrence risk in women with symptomatic
urinary tract infection. Int J Urol. 2014; 21:929-34. 
41. Loening-Baucke V. Urinary incontinence and urinary tract
infection and their resolution with treatment of chronic constipation
of childhood. Pediatrics. 1997; 100:228-32. 
42. Schaeffer AJ, Jones JM, Falkowski WS, et al. Variable adherence
of uropathogenic Escherichia coli to epithelial cells from women with
recurrent urinary tract infection. J Urol. 1982; 128:1227-30. 
43. Cai T, Caola I, Tessarolo F, et al. Solidago, Orthosiphon, Birch
and Cranberry extracts can decrease microbial colonization and
biofilm development in indwelling urinary catheter: a microbiologic
and ultrastructural pilot study. World J Urol. 2014; 32:1007-14. 
Correspondence
Tommaso Cai, MD (Corresponding Author) 
ktommy@libero.it
Irene Tamanini, MD
Department of Urology, Santa Chiara Regional Hospital, 
Largo Medaglie d'Oro 9 - 38123 Trento, Italy
Ekaterina Kulchavenya, MD
TB Research Institute, Novosibirsk 630040, Russia
Tamara Perepanova, MD
S.R. Urology Institute, Moscow 105425, Russia
Béla Köves, MD
Jahn Ferenc South Pest Teaching Hospital, 1204 Budapest, Hungary
Florian M.E. Wagenlehner, MD
Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, 
Universitätsklinikum Giessen und Marburg GmbH, Justus-Liebig-
Universität, 35392, Giessen, Germany
Zafer Tandogdu, MD
Northern Institute for Cancer Research, Newcastle University, 
NE1 7RU Newcastle upon-Tyne, UK
Gernot Bonkat, MD
Department of Urology, University Hospital Basel, University of Basel, 
Basel, Switzerland
Riccardo Bartoletti, MD
Dept. Translational Research and New Technologies, University of Pisa, 
56121 - Pisa, Italy
Truls E. Bjerklund Johansen,MD
Department of Urology, Oslo University Hospital, 0424 Oslo, Norway
Cai_Stesura Seveso  04/04/17  09:01  Pagina 6
